ABSTRACT

A medicament having inhibitory activity against NF-κB activation which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof:



(I)

wherein A represents hydrogen atom or acetyl group,

E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is ① a fused polycyclic heteroaryl group wherein the ring which binds directly to −CONH− group in the formula (I) is a benzene ring, ② unsubstituted thiazol-2-yl group, or ③ unsubstituted benzothiazol-2-yl group is excluded,

ring Z represents an arene which may have one or more substituents in addition to the group represented by formula −O−A wherein A has the same meaning as that defined above and the group represented by formula −CONH−E wherein E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula −O−A wherein A has the same meaning as that defined above and the group represented by formula −CONH−E wherein E has the same meaning as that defined above.